A detailed history of Charles Schwab Investment Management Inc transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 330,761 shares of OLMA stock, worth $1.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
330,761
Previous 123,196 168.48%
Holding current value
$1.78 Million
Previous $1.33 Million 196.47%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.41 - $16.46 $2.16 Million - $3.42 Million
207,565 Added 168.48%
330,761 $3.95 Million
Q2 2024

Aug 12, 2024

BUY
$8.73 - $13.99 $316,366 - $506,983
36,239 Added 41.67%
123,196 $1.33 Million
Q1 2024

May 08, 2024

SELL
$10.95 - $16.62 $24,670 - $37,444
-2,253 Reduced 2.53%
86,957 $984,000
Q4 2023

Feb 06, 2024

BUY
$10.53 - $17.14 $97,486 - $158,682
9,258 Added 11.58%
89,210 $1.25 Million
Q2 2023

Aug 09, 2023

BUY
$3.22 - $9.65 $197,617 - $592,239
61,372 Added 330.31%
79,952 $721,000
Q3 2022

Nov 14, 2022

SELL
$2.72 - $5.88 $322,825 - $697,873
-118,686 Reduced 86.46%
18,580 $52,000
Q2 2022

Aug 15, 2022

SELL
$2.04 - $4.61 $110,700 - $250,161
-54,265 Reduced 28.33%
137,266 $559,000
Q1 2022

May 13, 2022

SELL
$3.89 - $9.43 $43,097 - $104,474
-11,079 Reduced 5.47%
191,531 $816,000
Q4 2021

Feb 11, 2022

BUY
$8.75 - $30.71 $57,627 - $202,256
6,586 Added 3.36%
202,610 $1.9 Million
Q3 2021

Nov 16, 2021

BUY
$22.96 - $30.13 $2.63 Million - $3.45 Million
114,590 Added 140.72%
196,024 $5.4 Million
Q2 2021

Aug 16, 2021

BUY
$21.15 - $36.14 $59,600 - $101,842
2,818 Added 3.58%
81,434 $2.28 Million
Q1 2021

May 17, 2021

BUY
$27.81 - $53.64 $2.19 Million - $4.22 Million
78,616 New
78,616 $2.61 Million

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $217M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.